FY2024 EPS Estimates for Korro Bio Raised by William Blair

Korro Bio, Inc. (NASDAQ:KRRO) – Stock analysts at William Blair boosted their FY2024 EPS estimates for shares of Korro Bio in a note issued to investors on Wednesday, November 13th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($9.80) for the year, up from their prior estimate of ($10.56). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.63) per share. William Blair also issued estimates for Korro Bio’s Q4 2024 earnings at ($2.68) EPS, Q1 2025 earnings at ($2.79) EPS, Q2 2025 earnings at ($2.89) EPS, Q3 2025 earnings at ($2.93) EPS, Q4 2025 earnings at ($2.99) EPS, FY2025 earnings at ($11.60) EPS, FY2026 earnings at ($12.56) EPS, FY2027 earnings at ($13.59) EPS and FY2028 earnings at ($12.97) EPS.

Other equities analysts also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $115.00 price target on shares of Korro Bio in a report on Wednesday, November 13th. Royal Bank of Canada raised their target price on shares of Korro Bio from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Monday, October 21st. Finally, Raymond James started coverage on shares of Korro Bio in a research report on Monday, October 21st. They set a “strong-buy” rating and a $153.00 target price for the company. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $142.17.

Korro Bio Price Performance

Shares of KRRO stock opened at $46.63 on Monday. The stock’s 50 day simple moving average is $50.21 and its 200 day simple moving average is $46.59. Korro Bio has a twelve month low of $30.00 and a twelve month high of $98.00.

Korro Bio (NASDAQ:KRRO) last posted its earnings results on Tuesday, November 12th. The company reported ($2.26) earnings per share for the quarter, beating the consensus estimate of ($2.55) by $0.29.

Hedge Funds Weigh In On Korro Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Brown Brothers Harriman & Co. bought a new stake in shares of Korro Bio in the 2nd quarter worth approximately $28,000. Quest Partners LLC lifted its position in Korro Bio by 172.1% in the third quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock worth $59,000 after purchasing an additional 1,124 shares during the period. Vestcor Inc acquired a new stake in Korro Bio during the third quarter worth $100,000. MetLife Investment Management LLC increased its holdings in Korro Bio by 129.0% in the 3rd quarter. MetLife Investment Management LLC now owns 3,639 shares of the company’s stock valued at $122,000 after buying an additional 2,050 shares during the period. Finally, Lynx1 Capital Management LP bought a new stake in Korro Bio in the 2nd quarter valued at $129,000. 13.18% of the stock is currently owned by institutional investors.

Insider Transactions at Korro Bio

In related news, CFO Vineet Agarwal sold 800 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $70.00, for a total value of $56,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.40% of the stock is currently owned by corporate insiders.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).